As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries. For more information about Eisai Co., Ltd., please visit http://www.eisai.com. References
1. Motzer R, et al. Randomized phase 2 three-arm trial of lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma. The Lancet Oncology. 2015. Available at http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15) 00290-9/abstract
2. National Cancer Institue at the National Institute of Health. Available at: http://www.cancer.gov/types/kidney/patient/kidney-treatment-pdq. Accessed: October 2015
3. Cancer Network. NCCN Updates Kidney Cancer Guidelines to Incorporate FDA Approval of Everolimus. Available at:http://www.cancernetwork.com/kidney-cancer/nccn-updates-kidney-cancer-guidelines-incorp orate-fda-approval-everolimus. Assessed: October 2015
4. Matsui J et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 2008 Sep 1;14(17) :5459-65.
5. Matsui J et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008;122(3):664-71.
6. Okamoto K, et al. Distinct Binding Mode of Multikinase Inhibitor Lenvatinib Revealed by Biochemical Characterization. ACS Med. Chem. Lett 2015;6:89-94
7. Wu P et al. Small-molecule kinase inhibitors: an analysis of FDA-approved drugs. Drug Discovery Today 2015; 1-6
CONTACT: Media Enquiries: Eisai, Cressida Robson / Ben Speller, 16 Oct. (0) - 7908-314 155 / +44(0)7951-078-795, Cressida_Robson@eisai.net,Ben_Speller@eisai.net / Media Enquiries: Tonic Life Communications, AlexDavies / Emma Coughlan, +44(0)7720-496-472 / +44(0)7772-534-646,Alex.Davies@toniclc.com, Emma.Coughlan@toniclc.com
